„It has been a busy start to the year and we see an exciting year in front of us with US growth and progress with the skin barrier application.,“ says Simon Grant, CEO SciBase.
For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email:
Certified Advisor:
Vator Securities
Tel: +46 8 580 065 99
Email:
About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.
The post SciBase to present at the Redeye Medtech & Diagnostics Seminar on May 11, 2022 first appeared on Scibase.